Legal & General Group Plc Sells 16,109 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Legal & General Group Plc reduced its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 6.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 216,507 shares of the life sciences company’s stock after selling 16,109 shares during the period. Legal & General Group Plc owned approximately 0.28% of Integra LifeSciences worth $4,910,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Principal Financial Group Inc. raised its stake in Integra LifeSciences by 18.7% during the third quarter. Principal Financial Group Inc. now owns 401,432 shares of the life sciences company’s stock worth $7,294,000 after acquiring an additional 63,266 shares in the last quarter. Norges Bank acquired a new stake in shares of Integra LifeSciences during the 4th quarter worth about $8,967,000. Arrowstreet Capital Limited Partnership lifted its holdings in Integra LifeSciences by 7.1% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company’s stock valued at $312,000 after purchasing an additional 913 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in Integra LifeSciences by 599.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after buying an additional 2,800 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its stake in Integra LifeSciences by 33.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 19,755 shares of the life sciences company’s stock worth $448,000 after buying an additional 4,967 shares during the last quarter. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Stock Performance

Shares of NASDAQ:IART opened at $15.19 on Tuesday. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a 1-year low of $14.45 and a 1-year high of $32.66. The stock has a market capitalization of $1.17 billion, a P/E ratio of -168.76, a P/E/G ratio of 0.73 and a beta of 1.24. The business has a 50-day moving average price of $21.12 and a two-hundred day moving average price of $22.28.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.12. The business had revenue of $442.65 million for the quarter, compared to analyst estimates of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. Integra LifeSciences’s revenue was up 11.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.89 earnings per share. Equities analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on IART shares. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday, March 31st. Truist Financial reduced their price objective on Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating on the stock in a research note on Friday, April 11th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $22.71.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.